首页>投融资
OnKure
C轮
OnKure is a biotechnology company commercializing a new cancer therapy based on novel, less toxic kinase inhibitor drugs.on May 10, 2024, Reneo Pharmaceuticals, Inc., entered into an Agreement and Plan of Merger by and among the Company, Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC, and OnKure, Inc.. OnKure will become a wholly owned subsidiary of the Company (the “Merger”), which will change its name to “OnKure Therapeutics, Inc.”
基本信息
-
公司全称OnKure Inc
-
类型靶向小分子药物研发商
-
产业领域药品研发/制造、生物/化学技术
-
公司人数15人以下
-
地址6707 WINCHESTER CIRCLE SUITE 400 BOULDER COLORADO 80301; US; Telephone: +17203072892;
-
联系电话
-
邮箱info@shockingcreations.com
-
成立时间2015-01-01
投融资
-
2023-05-23C轮5400万美元鱼鹰资管BlackRockAcorn BioventuresDeep Track CapitalPerceptive AdvisorsSurveyor CapitalSamsara BioCapital
-
2021-03-04B轮5500万美元Samsara BioCapitalPerceptive AdvisorsBlackRock鱼鹰资管Surveyor CapitalAcorn Bioventures
-
2018-05-02A轮700万美元未透露
-
2015-07-07债权融资49.5万美元未透露
-
2013-06-04种子轮59.97万美元未透露
-
2012-05-23捐赠/众筹/授予25万美元未透露
- 加载更多
相关投融资企业
上市
Medicus Pharma Ltd.是一家生物技术/生命科学公司，专注于加速新型和颠覆性治疗资产的临床开发项目。通过我们丰富的经验和广泛的行业网络，我们正在将Medicus打造成一家领先的制药公司，致力于提供更好的治疗结果并减轻疼痛和痛苦。
A轮
LoQus23 is a Dementia Discovery Fund formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.In November 2021, LoQus23 Therapeutics Ltd announced the successful closing of its £7 million extended seed round
上市
OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS).In November 2020, OS Therapies announced the acquisition of all indications for OST-HER2 including Canine.In June 2021 Advaxis Inc licensing agreement with OS Therapies.In April 2021, OS Therapies announced the closing of a $6 million Series A round of funding
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息